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A B S T R A C T
Advanced Lipoxidation End-products (ALEs) are modiﬁed proteins that can act as pathogenic factors in several
chronic diseases. Several molecular mechanisms have so far been considered to explain the damaging action of
ALEs and among these a pathway involving the receptor for advanced glycation end products (RAGE) should be
considered. The aim of the present work is to understand if ALEs formed from lipid peroxidation derived reactive
carbonyl species (RCS) are able to act as RAGE binders and also to gain a deeper insight into the molecular
mechanisms involved in the protein-protein engagement. ALEs were produced in vitro, by incubating human
serum albumin (HSA) with 4-hydroxy-trans− 2-nonenal (HNE), acrolein (ACR) and malondialdehyde (MDA).
The identiﬁcation of ALEs was performed by MS. ALEs were then subjected to the VC1 Pull-Down assay (VC1 is
the ligand binding domain of RAGE) and the enrichment factor (the diﬀerence between the relative abundance
in the enriched sample minus the amount in the untreated one) as an index of aﬃnity, was determined.
Computation studies were then carried out to explain the factors governing the aﬃnity of the adducted moieties
and the site of interaction on adducted HSA for VC1-binding. The in silico analyses revealed the key role played
by those adducts which strongly reduce the basicity of the modiﬁed residues and thus occur at their neutral state
at physiological conditions (e.g. the MDA adducts, dihydropyridine-Lysine (DHPK) and N-2-pyrimidyl-ornithine
(NPO), and acrolein derivatives, N-(3-formyl-3,4-dehydro-piperidinyl) lysine, FDPK). These neutral adducts
become unable to stabilize ion-pairs with the surrounding negative residues which thus can contact the RAGE
positive residues.
In conclusion, ALEs derived from lipid peroxidation-RCS are binders of RAGE and this aﬃnity depends on the
eﬀect of the adduct moiety to reduce the basicity of the target amino acid and on the acid moieties surrounding
the aminoacidic target.
1. Introduction
The oxidative degradation of lipids (lipid peroxidation) results in
the formation of a wide variety of break-down products including small
molecules containing a carbonyl moiety and characterized by chemical
reactivity and for this reason called reactive carbonyl species (RCS) [1].
Lipid-derived reactive carbonyl species (RCS) are quite heterogeneous,
belonging to diﬀerent chemical classes including α,β-unsaturated al-
dehydes [4-hydroxynonenal (HNE), acrolein (ACR)], keto-aldehydes
[methylglyoxal (MGO), 4-oxo-nonenal (ONE)] and di-aldehydes [mal-
ondialdehyde (MDA) and glyoxal (GO)] [2]. RCS react with diﬀerent
nucleophilic substrates and in particular with the nucleophilic amino
acids of protein (arginine, lysine, cysteine and histidine) through a re-
action called protein lipoxidation and involving the carbonyl moiety
and the electrophilic center (e.g. the C3 of an α,β-unsaturated moiety).
The reaction products between proteins and RCS, advanced lipoxida-
tion products (ALEs), are now recognized not only as biomarker of RCS
formation but also as bioactive/damaging biomolecules [3,4]. More-
over, RCS are currently recognized as being involved in the onset and
progression of several diseases including diabetic retinopathy [5],
atherosclerosis [6], renal disease [7] and metabolic disorders [8]. Based
on their pathogenetic role, ALEs are now considered as promising drug
target and molecules eﬀective in preventing ALE formation have been
reported to have beneﬁcial eﬀects in some animal models [9,10].
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However, it should be considered that the eﬀect of protein lipoxidation
and of RCS can be double-sided, because besides a damaging me-
chanism as above mentioned, in some conditions and depending on
their levels, they can exert protective eﬀects associated with the in-
duction of antioxidant defense mechanisms [11].
Several molecular mechanisms have so far been considered to ex-
plain the damaging action of ALEs, which can include one of the fol-
lowing mechanisms, depending on the damaging process and the target
protein itself: protein dysfunction, protein oligomerization, signal
transduction and immune response [3,6]. Moreover, adduction of RCS
to proteins can also lead to the formation of ALEs acting as binders and
activators of some receptors as in the case of galectin-3, a glycan
binding protein which has been suggested to aid in the removal of
circulating AGEs and ALEs [12].
ALEs which are formed from RCS deriving either from lipid and
reducing sugar oxidation, such as glyoxal and methylglyoxal, (in this
paper called AGEs/ALEs) are known to act as binders and activators of
the receptor RAGE [13,14]. RAGE is a type I cell surface receptor that is
expressed in several cells, such as endothelial cells, smooth muscle cells,
but also dendritic cells and T-lymphocytes and is predominantly located
in the lungs [15]. RAGE has been involved in many diﬀerent patholo-
gies with a marked oxidative base, such as diabetes, atherosclerosis,
neurodegenerative diseases and many diﬀerent ligands of RAGE have
been identiﬁed, such as amyloid β peptide, S100/calgranulin protein,
HMGB1 [16]. Two diﬀerent pathways can be activated upon binding to
the receptor: 1) the activation of the NADPH oxidase, resulting in the
production of reactive oxygen species (ROS), which are detrimental to
the cells and 2) the activation of the NF-κB pathway leading to a sus-
tained pro-inﬂammatory and pro-ﬁbrotic response [17].
However, there are some ALEs (in this paper called as ALEs-lipox),
widely detected in several oxidative based and inﬂammatory diseases
[6,18], which are formed by RCS only deriving from a lipid peroxida-
tion process, such as MDA, HNE and ACR. For these ALEs-lipox very few
data are available on their RAGE interaction. Shanmugam et al. [19]
reported that synthetic ALE (malondialdehyde-lysine [MDA-Lys]) in-
duces oxidative stress and also activates the transcriptional factor nu-
clear factor-kB (NF-kB) in THP-1 monocytes partly via the receptor for
AGEs (RAGE).
The aim of the present paper is to understand whether ALEs-lipox
are able to act as RAGE binders as do AGEs and AGEs/ALEs and also to
gain a deeper insight into the molecular mechanisms involved in the
protein-protein engagement. Our starting hypothesis, the involvement
of ALEs-lipox in RAGE activation, is supported by several facts such as
that ALEs/AGEs and ALEs-lipox share some structural properties such
as the covalent modiﬁcations by aldehydes of nucleophilic residues and
that ALEs-lipox are pro-inﬂammatory and pro-ﬁbrotic compounds ac-
tivating the NF-kB pathway, a mechanism which could be addressed to
a RAGE activation pathway. Fig. 1 shows the work ﬂow of the study.
To test this hypothesis, a set of ALEs was ﬁrstly prepared and fully
characterized by MS. ALEs were formed using the well-known lipid
peroxidation derived RCS and in particular HNE, ACR and MDA. Since
ALEs are quite heterogeneous also when formed by a single attacking
RCS, for each tested RCS the diﬀerent ALEs were fully identiﬁed by a
bottom-up MS approach in terms of adducted moiety and modiﬁcation
site. The RAGE binding ability of each identiﬁed ALE was then de-
termined using the VC1 assay as previously reported [20]. For each
identiﬁed ALE the VC1 binding ability was then related to the variation
in the ionization state of the adducted residues as well as to the
abundance of surrounding negative residues that, after the ALE gen-
eration, become available for RAGE binding. Computation studies were
then carried out to explain the factors governing the aﬃnity of the
adducted moieties and the site of interaction on adducted HSA for VC1-
binding.
The overall data permit the elucidation of the structural require-
ments for ALEs to become RAGE binders together with the molecular
mechanisms involved in the protein-protein engagement.
2. Materials and methods
2.1. Reagents
Formic acid (FA), triﬂuoroacetic acid (TFA) and acetonitrile (ACN)
were LC-MS grade; sodium dodecyl sulfate (SDS), ammonium bi-
carbonate, malondialdehyde tetrabutylammonium salt (MDA-TS), ac-
rolein (ACR), HEPES, NaCl, sodium dihydrophosphate, disodium
phosphate and all other chemicals were analytical grade and purchased
from Sigma-Aldrich (Milan, Italy). 4-Hydroxy-2-trans-nonenal di-
methylacetal (HNE-DMA, catalog Number H9538) was purchased from
Sigma-Aldrich (Milan, Italy) and recombinant HSA expressed in P.
pastoris were purchased from Sigma Aldrich (Milan, Italy). Streptavidin-
coated magnetic beads (Streptavidin Mag Sepharose™) were purchased
from GE Healthcare (Milan, Italy)
Ultrapure water was prepared by a Milli-Q puriﬁcation system
(Millipore, Bedford, MA, USA).
Any KD ™ Mini Protean® TGX ™ precast gel, Standard Precision Plus
prestained protein standards, Laemmli sample buﬀer (2×/ 4×),
Running buﬀer and Bio-Safe Coomassie, together with the threo-1,4-
Dimercapto-2,3-butanediol (DTT) and iodoacetamide (IAA) were sup-
plied by Bio-Rad Laboratories, Inc. Trypsin and Chymotrypsin sequen-
cing grade were purchased from Roche Diagnostics SpA (Monza, Italy).
Digestion buﬀer was 50mM ammonium bicarbonate; destaining
solution was prepared mixing acetonitrile with digestion buﬀer (1:1 v/
v); reducing solution was 10mM DTT in digestion buﬀer; alkylating
solution was 55mM iodoacetamide in digestion buﬀer; extraction so-
lution was prepared as follows: 3% TFA/30% ACN in H2O MilliQ.
2.2. In vitro generation of ALEs-HSA
4-hydroxy-trans− 2-nonenal (HNE) was prepared as previously de-
scribed [21]. HSA modiﬁed with MDA was prepared dissolving HSA in
10mM phosphate buﬀer pH 7.4 at a concentration equal to 100 μM
(6.7mgml−1). HSA was incubated, as previously described [20] in the
dark at 37 °C and 400 rpm and using the following molar ratios between
protein and MDA: 1:6.3, 1:63, 1:630, 1:6300, 1: 12600. HSA modiﬁed
with ACR or HNE was prepared dissolving HSA in 10mM phosphate
buﬀer pH 7.4 at a concentration equal to 75 μM (5mgml−1). HSA was
incubated in the dark at 37 °C and at 400 rpm in molar ratios protein:
ACR equal to 1:10, 1:100, 1:1000, 1:2500 and 1:5000 and in molar
ration protein: HNE equal to 1:10, 1:100, 1:200, 1:1000 and 1:2000.
HSA incubated without RCS was used as a control untreated sample.
The reactions were stopped after 24, 48 or 72 h removing the excess of
RCS by ultraﬁltration using Amicon Ultra ﬁlter units 0.5 ml, cut-oﬀ
10 kDa (Millipore).
2.3. Intact protein analysis by MS
ALEs obtained by incubating HSA with RCSs were analyzed by di-
rect infusion on a triple-quadrupole (TQ) mass spectrometer (Finnigan
TSQ Quantum Ultra, ThermoQuest, Milan, Italy) equipped with an
Electrospray Finnigan Ion Max source. For MS analyses, samples were
desalted by using Amicon Ultra ﬁlter units 0.5ml, cut-oﬀ 10 kDa
(Millipore) and washed three times with water. Samples were then
diluted to 1 mgml−1 with a ﬁnal composition of CH3CN–H2O–HCOOH
(30:70:0.1, v/v/v). Aliquots of 50 μl were injected into the mass spec-
trometer at a ﬂow rate of 25 μl min−1 by using a ThermoQuest auto-
sampler. Each sample was analyzed for 5min under the following in-
strumental conditions: positive-ion mode; ESI voltage 3.5 kV, capillary
temperature 350 °C, Q3 scan range 1200–1500m/z, Q3 power 0.4 amu,
scan time 1 s, Q2 gas pressure 1.5 Torr, skimmer oﬀset 10 V, microscan
set to 3. Full instrument control and ESI mass spectra acquisitions were
carried out by Xcalibur software (version 2.0.7, Thermo Fisher
Scientiﬁc, Rodano, MI, Italy). Mass spectra deconvolution was per-
formed using MagTran software (version 1.02) [22].
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2.4. VC1 pull-down assay
VC1-His-Strep was expressed and puriﬁed from Pichia pastoris cul-
ture supernatant as previously described [23]. The recombinant protein
was immobilized on streptavidin-coated magnetic beads by exploiting
the aﬃnity of the Strep tag towards streptavidin. In order to obtain the
VC1-resin, 50 μg of puriﬁed VC1-His-Strep in 170 μl of 20mM HEPES
pH 7.1, 100mM NaCl were added to 5 μl of packed streptavidin coated-
beads, previously equilibrated with the same buﬀer. A volume of 170 μl
of 20mM HEPES pH 7.1, 100mM NaCl were added to the same amount
of beads in a diﬀerent tube in order to obtained the Control-resin. After
1 h of incubation at 4 °C on a rotary mixer, the unbound material was
carefully removed and the magnetic beads were washed with 500 μl of
buﬀer (20mM HEPES pH 7.1, 100mM NaCl). The VC1- and Control-
resin were incubated for 1 h at 4 °C with 160 μl of ALE-HSA or untreated
HSA at the concentration of 125 μgml−1 in 20mM HEPES pH 7.1,
100mM NaCl. The unbound material was carefully removed and the
beads were washed twice with 500 μl of Buﬀer (20mM HEPES pH 7.1,
100mM NaCl). The elution was performed by boiling the beads for
5min in 15 μl of Laemmli Sample Buﬀer 4x mixed with 400mM DTT,
then with other 15 μl of buﬀer (20mM HEPES pH 7.1, 100mM NaCl).
The two eluates were pooled.
2.5. Electrophoretic procedures
The fractions obtained from pull-down experiments were analyzed
by SDS PAGE. To 20 μl of input and unbound fractions, 7 μl of Laemmli
Sample Buﬀer 4x mixed with 400mM DTT were added. The samples
were denatured incubating for 5min at 95 °C. Input, unbound and
elution samples were separated by SDS-PAGE on Any KD ™ Mini
Protean® TGX ™ precast gels and stained with Bio-Safe Coomassie blue
(Bio-Rad). Images were acquired using the calibrated densitometer GS-
800 and analyzed by the software Quantity one (Bio-Rad).
2.6. ALE-HSA in-gel digestion
Proteins bands corresponding to ALEs-HSA and obtained by in-
cubating HSA with HNE, ACR and MDA (input), and those cut from the
fraction retained by VC1, were excised from gels using a scalpel, ﬁnely
chopped, transferred to a new eppendorf and washed with 200 μl of
digestion buﬀer. An aliquot of 200 μl of destaining solution was added
to each gel portion and heated at 37 °C for 10min in the thermomixer
(1400 rpm); the destaining solution was then discarded and this step
was repeated until destaining was completed. Afterwards, gel pieces
were incubated with 150 μl of reducing solution at 56 °C for 1 h and
then with 150 μl of alkylating solution at room temperature for 45min
in the dark. In-gel digestion of ALE-HSA adducts was performed by
overnight-incubation at 37 °C with 1 µg of sequencing-grade trypsin
(Roche) dissolved in digestion buﬀer. ALE-HSA samples were also
subjected to a second digestion by a sequencing-grade chymotrypsin
(1 µg) for 7 h at 25 °C in the presence of calcium chloride (10mM). The
peptide mixtures were acidiﬁed with formic acid up to a ﬁnal con-
centration of 1%.
To guarantee better protein detection, peptide mixtures were
Fig. 1. Work ﬂow of the study. ALEs-lipox were ﬁrstly prepared by incubating HSA with lipid peroxidation derived RCS (HNE, ACR and MDA) and then fully
characterized by MS. The RAGE binding ability of each identiﬁed ALE was then determined by using the VC1 assay as previously reported [20]. Computation studies
were then carried out to explain the factors governing the aﬃnity of the adducted moieties and the site of interaction on adducted HSA for VC1-binding.
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extracted by a 10min-incubation with extraction solution and by an
additional 10 min-incubation with pure acetonitrile. The two extracts
were combined and dried in a vacuum concentrator (Martin Christ.).
Digested peptide mixtures were then dissolved in an appropriate vo-
lume (20 μl) of 0.1% formic acid for mass spectrometry (MS) analysis.
2.7. Mass spectrometry analyses
Peptides from the in-gel digestion were separated by reversed-phase
(RP) nanoscale capillary liquid chromatography (nanoLC) and analyzed
by electrospray tandem mass spectrometry (ESI-MS/MS). For each
analysis 5 μl of solubilized peptides were injected onto a C18HALO
PicoFrit column (75mM x 10 cm, 2.7mM particles, pores 100 Å, New
Objective, USA) by means of an autosampler. Samples were loaded onto
the fused silica column at 400 nl/min of mobile phase consisting of 99%
of phase A and 1% of phase B (0.1% HCOOH in CH3CN) for 15min.
Peptide separation was performed with a 55min linear gradient of
phase B (1–35%). The separative gradient was followed by 5min at
80% of phase B to rinse the column, and 15min of 99% of phase A and
1% of phase B served to re-equilibrate the column to the initial con-
ditions. The nano-chromatographic system, an UltiMate 3000
RSLCnano System (Dionex), was connected to an LTQ-Orbitrap XL mass
spectrometer (Thermo Scientiﬁc Inc., Milan, Italy) equipped with a
nanospray ion source (dynamic nanospray probe, Thermo Scientiﬁc
Inc., Milan, Italy) set as follows: positive ion mode, spray voltage 1.8
Kv; capillary temperature 220 °C, capillary voltage 35 V; tube lens oﬀset
120 V. The LTQ-Orbitrap XL mass spectrometer was operated in data-
dependent acquisition mode (DDA) to acquire both the full MS spectra
and the MS/MS spectra. Full MS spectra were acquired in "proﬁle"
mode, by the Orbitrap (FT) analyzer, in a scanning range between 300
and 1500m/z, using a capillary temperature of 220 °C, AGC target
= 5×105 and resolving power 60,000 (FWHM at 400m/z). Tandem
mass spectra MS/MS were acquired by the Linear Ion Trap (LTQ) in CID
mode, automatically set to fragment the nine most intense ions in each
full MS spectrum (exceeding 1×104 counts) under the following con-
ditions: centroid mode, isolation width of the precursor ion of 2.5m/z,
AGC target 1×104 and normalized collision energy of 35 eV. Dynamic
exclusion was enabled (exclusion dynamics for 45 s for those ions ob-
served 3 times in 30 s). Charge state screening and monoisotopic pre-
cursor selection were enabled, singly and unassigned charged ions were
not fragmented. Xcalibur software (version 2.0.7, Thermo Scientiﬁc
Inc., Milan, Italy) was used to control the mass spectrometer.
2.8. Identiﬁcation and localization of protein adducts
The software Proteome Discoverer (version 1.3.0.339, Thermo
Scientiﬁc, USA), implemented with the algorithm SEQUEST, was used
to compare the experimental full and tandem mass spectra with the
theoretical ones obtained by the in silico digestion of the HSA sequence
(Uniprot P02768). Trypsin and chymotrypsin were selected as the
cleaving proteases, allowing a maximum of 2 missed cleavages. Peptide
and fragment ion tolerances were set to 5 ppm and 10 mmu, respec-
tively. Cysteine carbamidomethylation was set as ﬁx modiﬁcation
(+57.02147); methionine oxidation was allowed as a variable mod-
iﬁcation in addition to the known HNE-, ACR- or MDA-derived mod-
iﬁcations as listed in Table S1.
As a quality ﬁlter, only peptide with an Xcore value grater then 2.2
for doubly-charged peptides, 2.5 for triply-charged, 2.75 for quadruply-
charged peptide ions, and 3 for charge states quintuple or higher were
considered as genuine peptide identiﬁcations. To ensure the lowest
number of false positives, the mass values experimentally recorded
were further processed through a combined search with the Database
Decoy, where the protein sequences are inverted and randomized. This
operation allows the calculation of the false discovery rate (FDR) for
each match, so that all the proteins out of range of FDR between to 0.01
(strict) and 0.05 (relaxed) were rejected.
For the localization of ALE-deriving modiﬁcations, the MS/MS
spectra of modiﬁed peptides were manually inspected; for the conﬁdent
mapping of the modiﬁcation sites, spectra were requested to match the
expected ions (b and/or y) neighboring the modiﬁed amino acid residue
both at the N- and C-termini.
2.9. Semi-quantitative analysis of ALE-HSA adducts
The relative extent of each protein modiﬁcation has been calculated
by determining the amount of the modiﬁed peptide in respect to the
native one, by assuming that the ionization eﬃciency of the native and
the modiﬁed peptides are equal. In particular, the single ion traces (SIC)
of the native and modiﬁed peptides were ﬁrstly reconstituted by setting
as ﬁlter ion the m/z values of the corresponding precursor protonated
peptides. The peak areas were then automatically calculated by the
Qual Browser tool of the Xcalibur data system (version 2.0.7, Thermo
Scientiﬁc Inc., Milan, Italy) and then the relative abundance calculated
by using the Eq. (1).
=
+
Relative Abundance%
Modified Peptide Peak Area
(Modified Peptide Peak Area Native Peptide Peak Area)
*100
(1)
The relative abundance of each modiﬁed peptide was determined in
both the input and enriched samples. The retention eﬃciency of each
identiﬁed ALEs towards VC1 was then determined by the Enrichment
Factor value, calculated as the diﬀerences between the relative abun-
dance in the enriched sample minus the amount in the untreated one
(Enrichment factor= %VC1-%NoVC1).
2.10. Computational studies
The prediction of the pK values of the simulated adducts was per-
formed by PM7-based semi-empirical calculations using MOPAC [24].
The simulations involved simpliﬁed model compounds by focusing on
the adducted side chains and neglecting the backbone atoms. Speciﬁ-
cally, the predictions involved the FDPK, mono and double N-propenal
MA adducts of lysine. Indeed and as experimentally known, 2-amino
pyrimidine and dihydropyridine (i.e., NPO and DHPK adducts) are
neutral at physiological pH, while cyclic guanidines (see HTP0) retain
the strong basicity of the guanidine group. With regard to HSA protein,
the retrieved resolved structure (PDB Id 1A06) was used, after a pre-
liminary optimization, to calculate the negative residues within a 5 Å
radius sphere around each adducted residues and to generate the cor-
responding adducts as induced by MDA e ACR. As discussed in the
Results section, two adducted HSA structures were manually generated
using the VEGA suite of program [25]: the ﬁrst carrying all the ACR-
based adducts and the second structure with all the MDA-based ad-
ducts. The analysis was focused on Arg and Lys adducts only because
they are numerous enough to derive a sort of structure-aﬃnity re-
lationships (SAR). Similarly, these analyses do not consider the HNE-
induced modiﬁcations because they are too limited to develop clear
relationships. In order to allow a suitable reorganization of the en-
vironments around all inserted adducts, the minimized adducted HSA
structures underwent 1 ns of MD simulations by Namd [26] keeping the
backbone atoms constrained to avoid excessive distortions of the re-
solved folding. With regard to RAGE structure, the NMR-derived V
structure (PDB Id: 2mov) was prepared and utilized as done in previous
studies. Protein-protein docking was performed using GRAMM [27]
with the default parameters and generating 1000 complexes for each
adducted HSA structure.
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3. Results
3.1. Intact protein analysis of HSA and ALEs-HSA by MS
In order to investigate the interaction between RAGE and ALEs-
lipox, diﬀerent ALEs-lipox were produced in-vitro by incubating HSA
with diﬀerent concentrations of the well-known lipid derived RCS and
in particular: acrolein (ACR), malondialdehyde (MDA) and 4-hydroxy-
trans− 2-nonenal (HNE). After 24, 48 and 72 h, aliquots of the in-
cubation mixtures were withdrawn, and the reaction was stopped by
removing the excess of RCS by ultraﬁltration. Intact protein analysis by
direct infusion MS was used to evaluate the extent of HSA modiﬁca-
tions. Fig. 2 shows the spectra of native HSA (panel A) and HSA in-
cubated with increasing molar ratios of HNE [1:1 (B), 1:5 (C), 1:10 (D),
1:100 (E), 1:200 (F) and 1:1000 (G)]. Panel A) shows the MS-spectrum
(mass range between m/z 1400 and 1500) of native and non-modiﬁed
HSA, characterized by three sharp multicharged ions at m/z 1414.99,
1445.71 and 1477.87 relative to the three multicharged ions at 47+ ,
46+ and 45+ . When HSA was incubated with HNE in a 1:1M ratio,
besides the three peaks relative to native HSA, a new set of peaks at m/z
1418.43, 1449.15, and 1481.40 is detectable and relative to the HNE
Michael adduct of native HSA (MW shifted by 156 Da), as conﬁrmed in
Fig. 2. Direct infusion ESI-MS analysis of native and HNE-modiﬁed HSA. Mass spectra of HSA recorded in a mass range between m/z 1400 and 1500. A) Native
HSA shows sharp intense peaks referred to the charge ions 47+ , 46+ and 45+ ; the deconvoluted spectrum reports a MW 66,455 Da (H). When HSA is reacted with
HNE at increasing molar ratios 1:1 (B), 1:5 (C), 1:10 (D), additional peaks relative to HNE adducts appear. At higher molar ratios 1:100 (E), 1:200 (F) and 1:1000 (G)
the MS spectra lose resolution and become ﬂat due to the presence of multiple adducts. H) Deconvoluted spectra showing the MS of HSA and protein adducts. MS
spectra relative to HSA incubated with HNE at 1:100M ratio and higher cannot be deconvoluted due to the extent of modiﬁcation.
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the deconvoluted spectrum (panel H). The number of adducted HNE
moieties per molecule of HSA increases proportionally with the increase
of molar ratios reaching 3 and 5 HNE moles per mole of HSA at 1:5 and
1:10 HSA: HNE molar ratios, as also conﬁrmed by the deconvoluted
spectra (panel H shows the deconvoluted spectra HSA incubated in the
presence of HNE at a 1:5 M ratio). At higher HNE molar ratios (1:100,
1:200 and 1:1000, panels E, F and G, respectively) the MS spectra do
not show any detectable peaks due the formation of such a large
number of adducts and consequently of so many ions which cover the
m/z scan range thus eliminating the detection of sharp ions.
Intact protein analysis was also performed on ALEs-lipox formed by
incubating HSA with ACR and MDA, showing the same stepwise in-
crease of modiﬁcations with the higher amount of RCS incubated with
HSA (Supplementary Figs. 1 and 2).
Intact protein analysis well indicates that by using a wide range of
molar ratios and diﬀerent time-points a quite wide array of ALEs for
each tested RCS was generated.
3.2. Pull-down assay with modiﬁed albumins
In order to characterize ALE-lipox modiﬁcations selectively en-
riched by RAGE, we performed a VC1 pull-down assay as previously
described [20]. HSA and HSA treated with MDA, ACR or HNE were
assayed for binding to VC1-resins and to control resin. As expected,
unmodiﬁed HSA was not retained by the VC1-resin (Fig. 3, panel A).
HSA modiﬁed by MDA and ACR are characterized by a diﬀerent mi-
gration pattern on a SDS-PAGE analysis, with the appearance of oli-
gomeric bands proportional to the increase of the HSA-RCS molar ratio
(Fig. 3, panel B: HSA-MDA at 72 h, panel D: HSA-ACR 72 h, panel F:
HSA-HNE 72 h). At increasing molar ratios and incubation time, higher
amounts of albumin modiﬁed with MDA or ACR were eluted from the
VC1 resin, with a predominance of the high molecular weight (HMW)
species. The modiﬁed albumins were retained by the VC1-resin, but not
by the control resin, as shown in Fig. 3 (panel C: HSA-MDA molar ratio
1:12,600, 72 h; panel: E HSA-ACR molar ratio 1:5000, 72 h, panel: G
HSA-HNE molar ratio 1:2000, 72 h). The time course analysis and the
pull-down experiments with HSA-MDA have previously been published
[20]. The time course analysis and the pull-down experiments with
HSA-ACR and HSA-HNE are reported in Supplementary Fig. 3 and
Supplementary Fig. 4 respectively.
3.3. Identiﬁcation and localization of protein adducts by mass spectrometry
ALEs-lipox in the reaction mixtures and those enriched by VC1 were
analyzed by bottom-up MS in order to identify the PTMs and to localize
the amino acid residues involved in the protein adduct formation.
Tables 1 and 2 summarize the identiﬁed ALEs before and after VC1
enrichment, respectively. It should be noted that the tables summarize
the overall PTMs identiﬁed at diﬀerent molar ratios and incubation
times. The ALEs not retained (identiﬁed only in the input samples),
retained (identiﬁed after VC1 enrichment) and present in both input
and elution samples are reported in the Venn diagrams of Fig. 4.
With regard to MDA (Table 2), only di-hydropyridine adducts on
lysines (DHPK), and N-2-pyrimidyl-ornithine adducts on arginines
(NPO) were retained by VC1-domain. The n-propenal modiﬁcations of
lysine (NPK), largely identiﬁed before enrichment, were not identiﬁed
after the enrichment.
ACR induced a set of modiﬁcations which were identiﬁed only after
VC1 enrichment and in particular the N-(3-formyl-3,4-dehydro-piper-
idinyl) lysine (FDPK) modiﬁcations, the Michael adduct on cysteines,
the double Michael adduct of lysines, the Michael adduct of histidine,
the N-2-(4 hydroxy-tetrahydro-pyrimidyl) ornitine (propane-arginine,
HTPO) and the Nε-(3-methylpyridinium)-lysine (MP-lysine) (Table 2).
Most of the ALEs generated by HNE were found both before or after
enrichment, with the exception of few Michael adducts which were
selectively retained by VC1 (not detected before enrichment) (Table 2).
Interestingly, a novel + 138 Da adduct was detected on Arg209 and
Arg485 with HNE (novel cyclic aduct, HNE-CY, Table 2). In agreement
with the adducts which arginine yields with other RCS (as seen for ACR
and MDA) and by considering the well-known reactivity of the guani-
dine function [see for example [28]) this adduct can be supposed to
include a 2-amino pyrimidine scaﬀold even though its precise structural
characterization would require additional studies.
3.4. Semi-quantitative analysis of ALE-HSA adducts
A semiquantitative analysis reporting the relative abundance of
each modiﬁed peptide in respect of the native peptide was then carried
out for each identiﬁed modiﬁcation in both the input (% No VC1) and
enriched samples (%VC1). The values were then used to calculate the
enrichment factor (EF) calculated as reported in the method section.
The values of the EF range between − 100 and +100, where − 100
means that the modiﬁcation has not been retained at all by the VC1
domain (it is only present in the input but not in the enriched sample),
+ 100 means that the modiﬁcation has been identiﬁed because it is
enriched by the VC1 (the modiﬁcation is not detected in the input due
to low abundance) and 0 means that they are equally distributed.
Values between 0 and + 100 indicate that the modiﬁcation is retained
by VC1 and that the retention eﬃciency increases as the value increases
above 0.
In Fig. 5, panels A, B and C show the EF for ALEs-lipox obtained by
using MDA, ACR and HNE, respectively. Regarding MDA, an overview
analysis indicates that most of the N-Propenal-Lys and NPO adducts are
not retained, with a few exception, while DHPK modiﬁcations sig-
niﬁcantly increase the aﬃnity of ALEs. As better described in the
computational analysis paragraph the data indicate that for MDA, VC1
aﬃnity is determined by the nature of the adduct.
In the case of ACR, with some exceptions explained in the following
paragraph, the FDPK adduct is more eﬀective in respect to the mono
and bis Michael adducts in increasing the binding towards VC1. In the
case of HNE, most of the identiﬁed adducts were not found to be ef-
fective in increasing the retention aﬃnity with the exception of few
residues.
3.5. Computational results
With a view to rationalizing the key factors inﬂuencing the RAGE
binding of the monitored adducts, in silico studies were performed. They
were focused on the adducts on arginine and lysine residues as formed
by ACR and MDA since they are numerous, with a very broad range of
aﬃnity, thus allowing the development of clear structure-aﬃnity re-
lationships.
As a preamble it should be remembered that the RAGE-ligand in-
teracting regions (i.e. the VC1 domain) are characterized by a rich set of
positively charged residues especially in the V portion: the resulting
positive RAGE surface shows an understandable non-speciﬁc aﬃnity for
acidic proteins which can bind RAGE by stabilizing extended sets of salt
bridges. On these grounds, one may ﬁgure out that a given covalent
adduct can induce RAGE binding via two major mechanisms: it can
introduce acid moieties which directly contact the RAGE residues (as
seen for example with CML and CEL adducts) or it can reduce the ba-
sicity of the adducted residues. In this second indirect mechanism, the
adducts can elicit RAGE binding mostly because they are able to de-
stabilize ionic clusters on the protein surface and to liberate negatively
charged residues which enhance their accessibility and they become
available to stabilize ion-pairs with the positive RAGE residues.
The here monitored covalent adducts do not introduce negative
functions and thus they should induce RAGE binding by the second
indirect mechanism. Such a hypothesis implies that the monitored
RAGE binding might be explained by considering two major factors: the
basicity of the formed adducts and the number of the surrounding ne-
gatively charged residues. Indeed, when the generated adduct retains a
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marked basicity which renders the protonated form still predominant at
physiological pH, the surrounding negative residues would remain
shielded around it and unavailable to contact the RAGE residues. On
the other hand, an adduct devoid of surrounding negative residues
would be unable to induce strong ionic contacts with RAGE regardless
of its basicity. On these grounds the here reported in silico analyses can
be subdivided into three steps: in the ﬁrst, the basicity of the considered
adducts was predicted by semi-empirical calculations; in the second,
Fig. 3. Modiﬁed albumin obtained by incubation of re-
combinant HSA in the presence of diﬀerent molar ratio of
RCS and VC1 pull-down assay. A) VC1 pull-down assay with
untreated HSA. SDS PAGE analysis followed by Coomassie
staining of the modiﬁed HSA obtained by 72 h incubation with
the indicated molar ratio of RCS (panel B: MDA; panel D: ACR;
panel F: HNE). The highest molar ratio of HSA-MDA
(1:12,600), HSA-ACR (1:5000) or HSA-HNE (1:2000) were
used as input (IN) in the pull-down assays with the VC1 and
control (CTRL)-resins. The IN fractions, the unbound fractions
(UNB) and eluates (E) were analyzed by SDS-PAGE followed
by Coomassie staining. The gels show that untreated HSA does
not bind VC1 (panel A), whereas high MW species of HSA-
MDA (panel C), HSA-ACR (panel E) and HSA-HNE (panel G)
are retained by the VC1-resin, but not by the CTRL-resin. Since
the elution is performed in denaturing conditions, this step
removes any associated molecule from the resin, including the
two VC1 glycovariants (34 and 36 kDa) and streptavidin (Stv,
14 kDa), indicated by arrows.
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the number of surrounding negative residues was calculated by using
the reﬁned HSA structure and by considering the number of aspartates
and glutamates in a 5 Å radius sphere around each adducted residue.
Finally, protein-protein docking simulations were performed by con-
sidering the V-domain of RAGE and the adducted HSA structures. For
simplicity, the docking simulations involved the HSA structure in-
cluding simultaneously all found adducts. Such a strategy clearly re-
duces the computational time and allows synergistic eﬀects between
adjacent adducts to be revealed.
Fig. 6 shows the ALEs structures and for some of them reports the
predicted basicity for the considered adducts and reveals that they can
be subdivided into two main groups depending on whether they retain
part of the basicity of the unmodiﬁed residues or become non-ionizable
derivatives at physiological conditions. When focusing attention on
arginine adducts, N-2-pyrimidyl-ornithine (NPO, from MDA) is com-
pletely neutral at physiological pH, while HTPO retains a large part of
the arginines strong basicity. Similarly, and with regard to lysine ad-
ducts, the DHPK adduct (from MDA) is a neutral adduct, the single
Michael adduct (N-Propenal lysine, from MDA) is slightly less basic
than lysine (Δ=−0.6), while the double Michael adduct and the FDPK
derivative (from ACR) show a similarly reduced basicity (Δ=−2.0)
compared to the unmodiﬁed residue. In other words, and at physiolo-
gical conditions, one may assume that (a) RP and DHPK adducts are
always neutral, (b) HTPR and NP-lysine are still protonated, (c) double
MA and FDPK are in equilibrium between the two forms and the neutral
state can play a signiﬁcant role.
This simple observation can explain: (a) why NPO is the only argi-
nine adduct (considering both MDA and ACR) which shows some aﬃ-
nitive residues; (b) why the DHPK adducts show a retention eﬃciency
markedly higher than N-propenal-lysines (among the MDA-induced
lysine adducts) and (c) why double MA and FDPK show a comparable
retention eﬃciency (among the ACR-induced lysine adducts). In gen-
eral, one may conclude that the ionization properties of the monitored
adducts play a pivotal role in determining their overall aﬃnity towards
RAGE, while the binding of each single adduct might be rationalized by
considering its speciﬁc environment as discussed below.
Table S2 (supplementary material) compiles the number of negative
residues included within a 5 Å radius sphere around each adducted
residue and allows for some insightful considerations. With regard to
neutral arginine adducts (NPO), Table S2 (supplementary materials)
clearly evidences that the two highly aﬃnitive adducts are surrounded
by a markedly higher number of negative residues (5 for Arg10 and 4
for Arg472). Interestingly the other three NPO adducts showing a po-
sitive EF value (Arg117, Arg337 and Arg428) show 2 surrounding ne-
gative residues while all adducts with negative EF value show at most 1
residue.
The compiled results for lysine adducts appear to be less clear even
though one may observe that almost all aﬃnitive adducts possess more
than 2 surrounding residues. The more diﬃcult interpretability of the
data concerning the lysine adducts can be explained by considering that
(a) they include diﬀerent adducts with diﬀerent ionization properties
and (b) some adducts (e.g. DHPK) can be directly involved in RAGE
binding, thus requiring less surrounding negative residues. Moreover
and due to the very high number of adducted lysines one may ﬁgure out
synergistic eﬀects between adjacent lysine adducts which may generate
very extended ionic networks not conveniently described by con-
sidering 5 Å radius spheres.
Taken together, the obtained results seem to conﬁrm that the MDA
Table 1
List of the PTMs identiﬁed on the indicated Amino acid residues in the ALEs samples obtained by in vitro incubation of HSA with RCS.
PTMs Amino Acid residue
MDA N-propenal-Lysine (NPK) Lys12, Lys20, Lys41, Lys162, Lys174, Lys212, Lys225, Lys233, Lys140, Lys262, Lys274, Lys281, Lys323, Lys359, Lys351,
Lys372, Lys378, Lys389, Lys402, Lys414, Lys466, Lys475, Lys500, Lys525, Lys545, Lys564, Lys573, Lys574
dihydropyridine-lysine (DHPK) Lys41, Lys174, Lys225, Lys233, Lys274, Lys276, Lys313, Lys323, Lys359, Lys378, Lys389, Lys402, Lys466, Lys500,
Lys519, Lys545, Lys573
N-2-pyrimidyl-ornithine (NPO) Arg209, Arg218, Arg144, Arg145, Arg257, Arg337, Arg484
ACR Michael Adduct (N-propanal derivative) (ACR-
MA)
His39, Cys75, His128, Cys169, His338, Cys392, His510
N-2-(4 hydroxy-tetrahydro-pyrimidyl) ornitine
(propane-arginine, HTPO) Arg209, Arg257, Arg337
N,N-bispropenal-Lysine (2ACR-K-MA) Lys41, Lys73, Lys174
N-(3-formyl-3,4-dehydro-piperidinyl) lysine
(FDPK)
Lys174, Lys225, Lys233, Lys274, Lys323, Lys372, Lys378, Lys389, Lys500
HNE Michael adduct (HNE-MA) His105, Lys106, His242, His288, His338, Arg428
Schiﬀ Base (HNE-SB) Lys106
Novel cyclic adduct (HNE-CY) Arg209
2-pentyl-pyrrole (PP) Lys106
2,3 dihydro-pentyl-furan (DHPF) Cys53, His105, Cys448, Cys487
Table 2
List of the PTMs identiﬁed on the indicated Amino acid residues in the ALEs-HSA samples retained by VC1.
PTMs Amino Acid residue
MDA dihydropyridine-lysine (DHPK) Lys41, Lys51, Lys195, Lys205, Lys233, Lys274, Lys276, Lys313, Lys359, Lys378, Lys389,
Lys414, Lys432, Lys436, Lys466, Lys500, Lys541, Lys545, Lys560, Lys564, Lys574
N− 2-pyrimidyl-ornithine (NPO) Arg10, Arg117, Arg144, Arg257, Arg337, Arg428, Arg472
ACR Michael Adduct (N-propanal derivative) (ACR-MA) Cys200, His338, His510
N− 2-(4 hydroxy-tetrahydro-pyrimidyl) ornitine (propano-arginine,
HTPO)
Arg337
N,N-bispropenal-Lysine (2ACR-K-MA) Lys41
N-(3-formyl−3,4-dehydro-piperidinyl) lysine (FDPK) Lys225, Lys233, Lys262, Lys274, Lys323, Lys372, Lys378, Lys389, Lys500, Lys545
N-(3-Methylpyridinium)-lysine (MPK) Lys 233
HNE Michael adduct (HNE-MA) His105, Lys106, His242, Cys289, His288, His338, Arg428
Schiﬀ Base (HNE-SB) Lys106
Novel cyclic adduct (HNE-CY) Arg485
2-pentyl-pyrrole (PP) Lys106
2,3 dihydro-pentyl-furan (DHPF) His105, Cys476, Cys477, Cys487
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and ACR-induced adducts act as RAGE binders mostly when they occur
in their neutral state at physiological pH and thus they are able to de-
stabilize ionic clusters on protein surface and to liberate negatively
charged residues which are no longer shielded and expose their car-
boxylate groups with a sort of “ﬂowering eﬀect” which promotes ion-
pairing between adducted HSA and RAGE. With a view to conﬁrming
the supposed binding mechanism, the last part of these in silico studies
involved protein-protein docking simulations which were performed to
generate the corresponding RAGE-adducted HSA complexes. While
avoiding a systematic analysis of all simulated HSA adducts, some re-
presentative putative complexes will be presented in order to further
corroborate the proposed mechanism and to gain deeper insights on the
involved interactions.
Fig. 7 (panel A) shows the putative complex as computed for the
most aﬃnitive NPO adduct (Arg472, from MDA) and reveals that the
several negative residues surrounding the adduct are involved in an
extended network of ion-pairs with the RAGE residues. In detail,
Asp494 and Glu495 approach Arg70 of RAGE while Glu492 contacts
RAGE-Lys90. Interestingly and although the RAGE surface is rich in
positive residues, the complex also shows a salt bridge in which the
positive residue comes from the HSA surface as seen in the salt bridge
between RAGE-Glu88 and Arg410. It should be noted that also the si-
mulated NPO adduct is found to elicit a charge transfer interaction with
Fig. 4. Venn diagrams of the identiﬁed ALEs as reported in Table 1 and 2.
ALEs are reported as the modiﬁed amino acid residues. The upper diagram
refers to ALEs obtained by treating HSA with MDA, the middle with ACR and
the lower with HNE. The input reports ALEs not retained by VC1 and present
only in the input samples; VC1 are the ALEs identiﬁed only after VC1-enrich-
ment; the intersections report the ALEs found both in the input and VC1-en-
riched samples.
Fig. 5. Enrichment Factor (EF) graphical distribution. Enrichment Factor
(EF) graphical distribution by means of vertical scatter plot overviewing the
aﬃnity of each identiﬁed ALEs towards VC1; all EF values spotted have been
calculated as the diﬀerences between the relative abundance in the enriched
sample minus the amount in the untreated one (Enrichment factor= %VC1-%
NoVC1), and graphically grouped as: MDA-adducts (panel A), ACR-adducts
(panel B) and HNE-adducts (panel C).
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RAGE-Arg78. In this way, the interaction surface between HSA and
RAGE is stabilized by a rich set of ionic interactions which are clearly
promoted by the neutralization of Arg472 and which can explain the
observed RAGE binding.
Fig. 7 (panel B) shows the computed complex for a very aﬃnitive
DHPK adduct (Lys436, from MDA) and highlights the potential sy-
nergistic role between adjacent adducts as supposed above. Indeed, the
complex reveals that Lys433 is closely surrounded by several other
MDA-based adducts (i.e., DHPK432 and DHPK519 plus NPO-Arg117
and NPO-Arg428) which contribute to the overall binding by directly
interacting with the RAGE residues (see for example the reinforced H-
bonds that DHPK436 elicits with Arg78 and Arg94), and through the
surrounding negative residues (not reported in Fig. 7 for clarity). The
found ion-pairs include Arg78-Glu400, Arg94-Asp183, Lys80-Glu188
and Lys32-Glu396. Notably, all the reported adducts show a positive EF
value apart from DHPK519, whose poor results can be ascribed to the
shielding eﬀect played by the close Arg186 residue and which further
conﬁrms the key role of the ionizable surrounding residues.
Finally, Fig. 7 panel C reports the putative complex for a highly
aﬃnitive FPDK adduct (on Lys262, from ACR) and emphasizes the key
role played by the three negative residues surrounding it and which are
involved in clear ionic interactions with the positive RAGE residues.
Interestingly and despite such a favorable environment Lys262 does not
give aﬃnitive adducts with MDA. This ﬁnding can be explained by
considering that Lys262 generates only the ionized N-propenal adduct
with MDA. Such a result suggests that the ionization properties play a
largely dominant role which cannot be counteracted by the surrounding
negative residues. Remarkably, the ﬁgure describing the entire RAGE-
HSA complex shows that the ionic contacts are not limited to the region
surrounding the FPD adduct but additional salt bridges are present in
the entire contact surface. This suggests that the RAGE-HSA binding is
initially promoted by the focused set of ionic contacts which can be
stabilized around the adduct and then is reinforced by a more extended
set of additional ion-pairs which characterize the entire contact surface.
Notably, these additional contacts which do not involve adducted re-
sidues are per se unable to promote the RAGE-HSA binding but they
play a clearly beneﬁcial role in that the initial binding is triggered by
the contacts stabilized by the residues surrounding the adduct with a
sort of hierarchical mechanism which brings to mind that described for
protein folding.
Although the aﬃnity of the HNE-based adducts was not analyzed in
silico, the observed EF values of the peptides including Lys106 are in
clear agreement with the basicity of the detected adducts. Indeed, the
retention eﬃciency is found to be quite high for those adducts which
abrogate the lysine basicity (i.e. Schiﬀ base and 2-pentylpyrrole) to
markedly decrease when the adduct only slightly reduces the basicity as
in the Michael adduct.
Even though HSA is not the ideal protein target to study in-depth
the RAGE binding on cysteines since most HSA cysteines are involved in
disulﬁde bridges, the general incapacity of the cysteine adducts to bind
RAGE can be clearly rationalized in terms of the proposed ﬂowering
eﬀect. Carbonylation of cysteines does not result in neutralization of
Fig. 6. Chemical structures of ALEs-lipox formed by incubating HSA with MDA, ACR and HNE and identiﬁed by MS. For some ALEs the pK values are reported in
brackets.
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positively charged residues but conversely it can neutralize particularly
acid cysteines with an opposite and unfavorable electron-deﬁcient ef-
fect on the protein surface
4. Discussion
Much evidence indicates that the pro-inﬂammatory and pro-ﬁbrotic
eﬀects of AGEs and AGEs/ALEs are due, among other mechanisms, to
RAGE binding and activation [18,29–31]. The engagement mechanisms
between AGEs and RAGE are still not fully elucidated and great scien-
tiﬁc interest is now focused on understanding which are the structural
moieties of AGEs that turn a protein to a RAGE binder and hence to a
pro-inﬂammatory mediator. The study is further complicated by the
fact that AGEs and AGEs/ALEs are characterized by a wide
heterogeneity not only due to the variability of the adducted moieties
which diﬀer on the basis of the attacking RCS but also due to the
variable target protein and sites of modiﬁcation.
A rich set of positively charged residues represents a structural
feature of RAGE which could explain its binding properties with ligands
[32]. In particular such positive charges result in a positive RAGE
surface, which drives the engagement with ligands characterized by
acidic or in general negatively charge residues, able to stabilize the
protein-protein interaction by an extended set of salt bridges [33].
While considering that the RAGE binding is clearly promoted by those
AGEs/ALEs, which are characterized by the presence of carboxylic
moieties such as CML and CEL [13], the mechanisms, by which a local
and structurally limited modiﬁcation, such as that induced by a AGE/
ALE adduct, can trigger the RAGE aﬃnity in large biomacromolecules,
Fig. 7. Putative RAGE-HSA complex as computed by protein-protein docking and induced by RP-Arg472 (6 A), DHPK-Lys436 (6B) and FDP-Lys262 (6 C). For each
simulated adduct, the right panel shows the entire RAGE-HSA complex while the left panel focuses on key interactions stabilized by the adduct and its surrounding
residues.
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are still not precisely understood. This lack of understanding is even
more pronounced when considering that many AGEs and almost all
ALEs (see below) do not introduce acid functions but at most they
modulate the basicity of the adducted residues.
While on one hand several studies have reported on the engagement
between AGEs and AGEs/ALEs on VC1 and RAGE, on the other, little is
known about the eﬀect of ALEs from RCS formed only by lipid perox-
idation such as HNE, MDA and ACR. These ALEs, here called ALEs-
lipox, are formed abundantly in several oxidative based conditions and
their damaging property has been widely reported. Several molecular
mechanisms have been suggested to explain the ALEs-lipox damaging
eﬀect and among these are protein dysfunction, protein oligomeriza-
tion, signal transduction and immune response [19]. Moreover, by
considering a pro-inﬂammatory and pro-ﬁbrotic response induced by
ALEs-lipox, a RAGE dependent mechanism could also be considered.
In the present report we have evaluated the binding property of a
wide set of ALEs-lipox formed by incubating HSA with the three most
abundant lipid peroxidation RCS, namely HNE, ACR and MDA. The
wide set of modiﬁcations were achieved by incubating the target pro-
tein with RCS at diﬀerent molar ratios and time points as conﬁrmed by
MS intact protein analysis.
The high concentrations of the aldehydes and in particular their
content in high molar excess in respect to the substrate, very far from
biological conditions, were used in order to obtain the maximum
number of adducts which can be generated from the reaction of RCS
with the protein substrate. Although the resulting ALEs are not char-
acterized by acid moieties, as reported in the literature and here con-
ﬁrmed by bottom-up analyses, we found using a VC1 pull-down assay
that some of the generated ALEs bind to the VC1. This is a quite novel
ﬁnding since to our knowledge no study has so far reported the ability
of ALEs from lipid peroxidation RCS to interact with VC1. The VC1
binding assay coupled to a high resolution MS approach has also per-
mitted the identiﬁcation of which ALEs moieties are responsible for the
VC1 binding and the sites of modiﬁcation. The wide set of data and in
particular the chemical diversity of the structures identiﬁed as binder
and non binder, have also permitted a SAR study leading to the mole-
cular explanation of why only some ALEs bind to VC1. As shown in
Fig. 8, besides the well known VC1 engagement based on the acid re-
sidues of the protein ligand, we here found another potential me-
chanism which may involve adducts that do not introduce acid groups
but only reduce the basicity of the modiﬁed residues. The mechanism,
called the ﬂowering eﬀect, is based on a two-step process and involves
exposed basic residues (mainly Lys and Arg) which in the non-adducted
protein form a set of ionic bridges with the carboxylic groups of sur-
rounding aspartate and glutamate residues. In the ﬁrst step, the RCS
form a covalent adduct with the positively charged residues, abolishing
or greatly reducing their basicity. Consequently, the adducted residues
are present in their neutral form at physiological conditions and such a
change in their ionization state destabilizes the ionic bridges and ren-
ders the surrounding anionic residues more accessible and available to
stabilize ion-pairs with the positive RAGE residues. Such a mechanism
explains why only one set of the identiﬁed ALEs acts as RAGE binder. In
other words we found the basic features that make an ALE a RAGE
binder and which strictly depend on the type of the adduct and on the
site of modiﬁcation. In particular we found that only some of the sev-
eral adducts formed by lipid peroxidation RCS abolish or greatly reduce
the basicity of the target amino acids and among these RP (from MDA)
and DHPK adducts are always neutral while HTPR, MA-Arg and NP-
lysine do not aﬀect the basic character. The second requirement is the
presence of a cluster of negative side chains surrounding the target
residue, which then becomes available to RAGE positive charges once
the amino acid is modiﬁed, thus stabilizing the protein-protein com-
plex.
We currently do not know whether ALEs-VC1 binding elicits RAGE
activation and hence if they lead a RAGE-dependent biological re-
sponse. Some studies such as that by Shanmugam et al. [34] reporting
that ALEs from MDA can induce a RAGE dependent biological response,
would suggest this. We are now working on this aspect by using cell
models and ALEs enriched by the VC1 assay as potential RAGE acti-
vators.
5. Conclusions
In summary by using an integrated MS (intact protein and bottom-
up approach) and computational approach we have found that some
ALEs generated from lipid peroxidation RCS are RAGE binders. We
have also found the basic features that ALEs from HNE, MDA and ACR
must have to be a RAGE binder: 1) the covalent adducts should greatly
reduce or abolish the basicity of the target amino acid, 2) the basic
amino acid should be at the center of a set of carboxylic acids which,
once the residue is modiﬁed, become available to freely contact the
RAGE positive residues. Interestingly, the here proposed ﬂowering eﬀect
can also be involved in the RAGE binding of the adducts which insert an
acid function. Indeed and besides the direct contacts stabilized by the
adduct, one may suppose that introduced anionic function exerts a si-
milar eﬀect on the surrounding negative residues thus promoting their
ionic interactions with the positive residues on RAGE surface. Stated
diﬀerently, the ﬂowering eﬀect might be a common mechanism trig-
gering the aﬃnity of adducted proteins towards RAGE even though it
signiﬁcantly increases its relevance for the adducts that do not add
Fig. 8. Mechanism explaining AGEs/ALEs
and ALEs-lipox binding to VC1. A) VC1 en-
gagement based on the acid residues of the
protein ligand. Such a mechanism occurs when
RCS, such as GO and MGO react with the basic
residue forming a carboxylated adduct (CML
and CEL) which directly contacts the RAGE
residues. B) Panel B summarizes the me-
chanism described in the present paper for
explaining the binding of ALEs-lipox to VC1
and called the “ﬂowering eﬀect”. It is based on a
two-step process and involves exposed basic
residues (mainly Lys and Arg) which in the
non-adducted protein form a set of ionic
bridges with the carboxylic groups of sur-
rounding aspartate and glutamate residues.
Lipid peroxidation derived RCS react with the
basic residue and abolish or greatly reduce
their basicity. Consequently, the adducted re-
sidues shift in a neutral form and such a change in the ionization state destabilizes the ionic bridges and renders the surrounding anionic residues more accessible and
available to stabilize ion-pairs with the positive RAGE residues.
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carboxylic functions such as those as seen here.
Moreover, one may expect that such a mechanism can modulate the
aﬃnity of carbonylated proteins towards a variety of target proteins not
necessarily limited to RAGE. More generally and since a similar me-
chanism was proposed to explain the protein-protein interactions trig-
gered by the acetylation of lysines, one may hypothesize that the ionic
perturbation of the protein surface, that shifts from a polyzwitterionic
situation to a polyanionic or polycationic condition, can be a general
mechanism, by which post translational modiﬁcations involving ioniz-
able side chains modulate the interacting capacity of the modiﬁed
proteins.
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